Transitional Cell Carcinoma Withdrawn Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04179110Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorTreatment